Sodium-glucose cotransporter (SGLT2) inhibitors have demonstrated cardiovascular (CV) benefits in large-scale clinical trials of people who have type 2 diabetes and either established CV disease or multiple CV risk factors. These studies also indicated early signals in benefiting heart failure (HF) patients and those with chronic kidney diseases. This article reviews recent and future clinical studies that focus on evaluation of the use of SGLT2 inhibitors in HF management and renal protection.
ZinmanBWannerCLachinJM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi:10.1056/NEJMoa1504720
2.
WiviottSDRazIBonacaMP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-357. doi:10.1056/NEJMoa1812389
3.
NealBPerkovicVMahaffeyKW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657. doi:10.1056/NEJMoa1611925
4.
GreeneSJVaduganathanMKhanMS, et al. Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes. J Am Coll Cardiol. 2018;71:1379-1390. doi:10.1016/j.jacc.2018.01.047
5.
PerkovicVJardineMJNealB, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-2306. doi:10.1056/NEJMoa1811744
ZelnikerTABraunwaldE.Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72:1845-1855. doi:10.1016/j.jacc.2018.06.040
10.
PrattichizzoFDe NigrisVMicheloniSLa SalaLCerielloA.Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component. Diabetes Obes Metab. 2018;20:2515-2522. doi:10.1111/dom.13488
11.
InzucchiSEKosiborodMFitchettD, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018;138:1904-1907. doi:10.1161/circulationaha.118.035759
12.
PackerMAnkerSDButlerJFilippatosGZannaF.Effect of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2:1025-1029. doi:10.1001/jamacardio.2017.2275
13.
PackerM.Reconceptualization of the molecular mechanism by which sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure events. Circulation. 2019;140:443-445. doi:10.1161/CIRCULATIONAHA.119.040909
14.
KatoETSlivermanMGMosenzonO, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139:2528-2536. doi:10.1161/CIRCULATIONAHA.119.040130
15.
McMurrayJJVSolomonSDInzucchiSE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008. doi:10.1056/NEJMoa1911303
16.
NassifMEWindsorSLTangF.Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF Trial. Circulation. 2019;140:1463-1476. doi:10.1161/CIRCULATIONAHA.119.042929
ClinicalTrials.gov. Dapagliflozin in PRESERVED ejection fraction Heart Failure (PRESERVED-HF). Published January 24, 2017. Accessed May 16, 2020. https://clinicaltrials.gov/ct2/show/NCT03030235
21.
ClinicalTrials.gov. Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. (DELIVER). Published August 7, 2018. Accessed March 30, 2020. https://clinicaltrials.gov/ct2/show/NCT03619213
22.
MarkhamAKeamSJ.Sotagliflozin: first global approval. Drugs. 2019;79:1023-1029. doi:10.1007/s40265-019-01146-5
ClinicalTrials.gov. Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial). Published May 11, 2018. Accessed May 12, 2020. https://clinicaltrials.gov/ct2/show/NCT03521934
ClinicalTrials.gov. Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED). Published October 19, 2017. Accessed March 30, 2020. https://clinicaltrials.gov/ct2/show/NCT03315143
27.
ClinicalTrials.gov. EMPA-KIDNEY (the Study of Heart and Kidney Protection With Empagliflozin). Published July 20, 2018. Accessed March 30, 2020. https://clinicaltrials.gov/ct2/show/NCT03594110
28.
ArnottCLiQKangA, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9:e014908. doi:10.1161/JAHA.119.014908
29.
DunlaySMGivertzMMAguilarD, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140:e294-e324. doi:10.1161/CIR.0000000000000691
30.
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment:Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(suppl 1):S98-S110. doi:10.2337/dc20-S009
31.
CosentinoFGrantPJAboyansV, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255-323. doi:10.1093/eurheartj/ehz486
32.
HonigbergMCVardenyOVaduganathanM.Practical considerations for the use of sodium-glucose co-transporter 2 inhibitors in heart failure. Circ Heart Fail. 2020;13:e006623. doi:10.1161/CIRCHEARTFAILURE
